Jan zur Hausen is to join DVC Deutsche Venture Capital in January 2004, when he will become the sixth member of its life sciences investment team.
Zur Hausen was previously at Hamburg-based investment firm Mulligan BioCapital, which he joined in 2000 and where he had joint responsibility for building a portfolio of ten European and US biotechnology companies.
Prior to this, zur Hausen was responsible for technological and financial assessments of private equity investments in biotechnology and medical device companies at MPM Asset Management in San Francisco.
From 1996 to 1998, he was scientific analyst for management consulting and advisory firm MPM Capital Advisors, where he participated in Bayer’s acquisition of a stake in Millennium Pharmaceuticals – one of the largest collaborations to date between a pharmaceutical and biotechnology company.
In his new role, zur Hausen will report to Joerg Neermann, managing partner of the life sciences team, which has a current portfolio of 13 life sciences investments. In April 2003, it invested around E5m in the third-round financing of Epigenomics, a biotech company developing DNA methylation-based products for early detection and molecular classification of cancer and other diseases.
DVC focuses on European information, telecommunication, semiconductor and industrial technologies as well as life sciences. In life sciences, it looks for opportunities in therapeutic and diagnostic product development as well as platform technologies and medical devices. It invests around E1m to E10m as a lead or co-lead investor and has backed around 50 companies since formation in 1998.